Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Remitogen

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

apolizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
Novel antigenic targets for immunotherapy in myeloma
  • Q. Yi
  • 2009
    • Corpus ID: 72405595
Multiple myeloma (MM) is the second most commonly diagnosed hematologic malignancy after non-Hodgkin lymphoma and remains… Expand
Review
2003
Review
2003
Commentary (O'Brien): Current Status of Monoclonal Antibody Therapy for Chronic Lymphocytic Leukemia
Dr. Nabhan and his coauthors have written a comprehensive review of the use of monoclonal antibodies in the treatment of chronic… Expand
2002
2002
In Vivo Pharmacodynamic Effects of Hu1D10 (Remitogen), a Humanized Antibody Reactive Against a Polymorphic Determinant of HLA-DR Expressed on B Cells
The humanized monoclonal antibody Hu1D10 (Remitogen™3;, Protein Design Labs, Fremont, CA) recognizes a polymorphic determinant of… Expand
2002
2002
Enhanced killing of B lymphoma cells by granulocyte colony‐stimulating factor‐primed effector cells and Hu1D10 – a humanized human leucocyte antigen DR antibody
Summary. Antibody‐based approaches have become a novel treatment modality for lymphoma patients. Humanized 1D10 (Hu1D10… Expand
2002
2002
Protein design labs begins Phase I trial of Remitogen in cancer patients with solid tumors.
  • Expert review of anticancer therapy
  • 2002
    • Corpus ID: 34566663
 
2001
2001
Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma.
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE